Paper Details

  1. Home
  2. Paper Details

The times they are a-changin': new antibacterials for skin and skin structure infections.

Author: GoldsteinEllie J C, NaumovskiSnezana, TranMai-Chi N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discussed the therapeutic efficacy of five new agents for the therapy of skin and soft tissue infections.
Paper Details　
Original Abstract of the Article :
Twenty-one agents are approved by the US Food and Drug Administration (FDA) for the therapy of skin and soft tissue infections. Of these, the five newest agents, tedizolid, telavancin, oritavancin, dalbavancin, and ceftaroline, are active against and "non-inferior" to vancomycin against methicillin-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40257-015-0125-9

データ提供：米国国立医学図書館（NLM）

New Antibacterials for Skin and Skin Structure Infections: A New Oasis in the Desert of Drug Resistance

This research delves into the landscape of new antibacterial agents approved for treating skin and skin structure infections. It’s like discovering a new oasis in the vast desert of drug resistance, offering hope for patients battling stubborn infections. The authors review the spectra of activity, clinical trials, and therapeutic efficacy of five novel antibacterial agents: tedizolid, telavancin, oritavancin, dalbavancin, and ceftaroline. These agents demonstrate activity against methicillin-resistant Staphylococcus aureus (MRSA), a formidable foe in the world of infections. The research highlights the emergence of new weapons in the fight against resistant bacteria, offering a glimmer of hope in the face of a growing global challenge.

The Desert of Drug Resistance: A Battle for Survival

This research underscores the importance of developing new antibacterials to combat the rising threat of drug resistance. It’s like searching for new sources of water in a desert that is rapidly drying up. The findings offer a promising glimpse into the future of antibacterial therapy, where new strategies are emerging to combat the growing threat of drug-resistant infections.

New Antibacterials: A New Spring in the Desert

This research brings a sense of hope for patients battling skin and skin structure infections, especially those caused by drug-resistant bacteria. It’s like discovering a new spring in a parched desert, offering a source of revitalization and relief.

Dr. Camel's Conclusion

This research highlights the ongoing battle against drug resistance and the development of new antibacterial agents. It’s like navigating a desert, where finding new sources of water is essential for survival. The research underscores the importance of continued innovation and research to ensure effective treatment options for a wide range of infections.

Date :
  1. Date Completed 2016-01-27
  2. Date Revised 2016-07-07
Further Info :

Pubmed ID

25906205

DOI: Digital Object Identifier

10.1007/s40257-015-0125-9

Related Literature

Article Analysis
・Side Effects of tedizolid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.